Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination

Պահպանված է:

Մատենագիտական մանրամասներ
Հիմնական հեղինակ:	Feng Wang (44414) (author)
Այլ հեղինակներ:	Yang Liu (3703639) (author), Wanglong Qiu (710981) (author), Elaine Shum (14955138) (author), Monica Feng (9566474) (author), Dejian Zhao (14955141) (author), Deyou Zheng (12490640) (author), Alain Borczuk (451970) (author), Haiying Cheng (4787832) (author), Balazs Halmos (5171009) (author)
Հրապարակվել է:	2025
Խորագրեր:	Cancer Cancer Biology Tumor Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Signaling Receptors Drug Targets Cell surface receptor drug targets Gene Technologies High-throughput sequencing Lung Cancer Oncogenes & Tumor Suppressors Oncogenes Progression, Invasion & Metastasis Small Molecule Agents Translational Research
Ցուցիչներ:	Ավելացրեք ցուցիչ Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!

Նմանատիպ նյութեր

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
‌: Feng Wang (44414)
Հրապարակվել է: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
‌: Feng Wang (44414)
Հրապարակվել է: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
‌: Feng Wang (44414)
Հրապարակվել է: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
‌: Anne-Florence Blandin (15056366)
Հրապարակվել է: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
‌: Anne-Florence Blandin (15056366)
Հրապարակվել է: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
‌: Anne-Florence Blandin (15056366)
Հրապարակվել է: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
‌: Anne-Florence Blandin (15056366)
Հրապարակվել է: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
‌: Anne-Florence Blandin (15056366)
Հրապարակվել է: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
‌: Anne-Florence Blandin (15056366)
Հրապարակվել է: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
‌: Anne-Florence Blandin (15056366)
Հրապարակվել է: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
‌: Smruthy Sivakumar (15053536)
Հրապարակվել է: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
‌: Ana Vujovic (15207479)
Հրապարակվել է: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
‌: Katie E. Hebron (15046889)
Հրապարակվել է: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
‌: Katie E. Hebron (15046889)
Հրապարակվել է: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
‌: Katie E. Hebron (15046889)
Հրապարակվել է: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
‌: Katie E. Hebron (15046889)
Հրապարակվել է: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
‌: Katie E. Hebron (15046889)
Հրապարակվել է: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
‌: Katie E. Hebron (15046889)
Հրապարակվել է: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
‌: Katie E. Hebron (15046889)
Հրապարակվել է: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
‌: Yuanqing Ma (15052437)
Հրապարակվել է: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
‌: Yuanqing Ma (15052437)
Հրապարակվել է: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
‌: Yuanqing Ma (15052437)
Հրապարակվել է: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
‌: Yuanqing Ma (15052437)
Հրապարակվել է: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
‌: Yuanqing Ma (15052437)
Հրապարակվել է: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
‌: Yuanqing Ma (15052437)
Հրապարակվել է: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
‌: Yuanqing Ma (15052437)
Հրապարակվել է: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
‌: Yuanqing Ma (15052437)
Հրապարակվել է: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
‌: Srivandana Akshintala (16610490)
Հրապարակվել է: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
‌: Srivandana Akshintala (16610490)
Հրապարակվել է: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
‌: Yuncheng Bei (16546095)
Հրապարակվել է: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
‌: Yuncheng Bei (16546095)
Հրապարակվել է: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
‌: Yuncheng Bei (16546095)
Հրապարակվել է: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lpc1p65rem52k15ffuirpp956h